- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03738007
Clinical Study to Evaluate the Correction of Facial Wrinkles and Folds and Safety of YVOIRE Volume Versus Perlane in Nasolabial Fold Injection
November 21, 2018 updated by: LG Life Sciences
A Randomized, Multi Center, Single-blind, Active-controlled, Matched Pairs Design Clinical Study to Evaluate the Correction of Facial Wrinkles and Folds and Safety of HA IDF II Versus Perlane in Nasolabial Fold Injection
This study was purposed to evaluate the non-inferiority of YVOIRE volume, a hyaluronic acid product, in terms of correction of wrinkles and safety in nasolabial fold deep-dermal injection, compared to Perlane, the control preparation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
57
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: Women in 30~55 years.
- Those whose wrinkle scores in the treatment site (nasolabial fold) at the screening visit were Stage 3 or 4 in the 5-stage Wrinkle Severity Rating Scale (WSRS) symmetrically
- Those who were informed on this study in detail, understood it completely, decided to participate in the study own their own and signed on the informed consent form.
Exclusion Criteria:
- Those with a skin disease in the face (skin infection, eczema, psoriasis, rosacea, herpes etc.)
- Those with a history of severe allergy
- Those with hypertrophic scar or a history of kelloid
- Patients with an autoimmune disease
- Those with hepatic dysfunction or abnormality in coagulation, or those administering an anticoagulant (aspirin, warfarin etc.) concomitantly
- Those who had used a local topical preparation (steroid, retinoid) within 4 weeks prior to the study
- Those who had underwent a chemical peeling, laser procedure (including IPL) or insertion of other bioadaptive materials (however, those who had been treated with HA filler could participate in the study if the date of treatment was known and the investigator judged that the filler effect had disappeared).
- Patients with a malignant tumor
- Women in pregnancy or lactation
- Hepatitis carriers or VDRL/HIV positive patients
- Those with a hypersensitivity to the investigational medical device of this study
- Other persons including those considered as difficult to perform this study by the principal investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HA IDF II
|
Treatment with HA IDF II (YVOIRE volume)
|
Active Comparator: Perlane
|
Treatment with Perlane
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average of Wrinkle Severity Rating Scale (WSRS) score evaluated by the evaluating investigator at Week 26 (Visit 7) after the final treatment with the investigational medical device.
Time Frame: Week 26 (Visit 7)
|
Wrinkle Severity Rating Scale (WSRS)
|
Week 26 (Visit 7)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2010
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
November 9, 2018
First Submitted That Met QC Criteria
November 9, 2018
First Posted (Actual)
November 13, 2018
Study Record Updates
Last Update Posted (Actual)
November 26, 2018
Last Update Submitted That Met QC Criteria
November 21, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- LG-HACL009
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Temporary Correction of Wrinkles
-
LG Life SciencesCompleted
-
Merz Pharmaceuticals GmbHCompletedCorrection of Facial Wrinkles/Folds | Facial Volume EnhancementGermany
-
Gérond'ifTerminatedPatients Beneficiting of Temporary HebergementFrance
-
LG ChemCompleted
-
LG Life SciencesCompletedCorrection of Nasolabial Folds
-
LG Life SciencesCompletedCorrection of Nasolabial FoldsChina
-
Croma-Pharma GmbHCompletedPost Market Study Evaluating Princess Filler Lidocaine for the Correction of Nasolabial Folds (FINO)Correction of Nasolabial FoldsAustria
-
Across Co., Ltd.CompletedCorrection of Nasolabial FoldsKorea, Republic of
-
Jeanne et Leon DeveloppementGerontopôle des Pays de la LoireRecruitingResidents's Frailty in Temporary Accommodation | Residents's Quality of Life in Temporary AccommodationFrance
-
Bohus Biotech ABCompletedCorrection of Nasolabial FoldsSweden
Clinical Trials on HA IDF II
-
LG Life SciencesCompleted
-
LG Life SciencesCompleted
-
LG Life SciencesCompleted
-
Universitair Ziekenhuis BrusselActive, not recruitingCarotid Artery Plaque | Aneurysm | Aortic AneurysmBelgium
-
Universitair Ziekenhuis BrusselWithdrawnSurgery--ComplicationsBelgium
-
Ain Shams UniversityCompletedDiabetes Mellitus, Type 1 | FastingEgypt
-
NHS LothianUniversity of EdinburghRecruitingHip Dysplasia | Hip Osteoarthritis | Hip Arthropathy | Arthritis of HipUnited Kingdom
-
Medical Centre LeeuwardenCompletedSurgery | Hypovolemic ShockNetherlands
-
National Cancer Centre, SingaporeSingapore General Hospital; Singhealth Duke-NUS Oncology Academic Clinical...Active, not recruiting
-
Region SkaneActive, not recruiting